BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Conference / presentation

MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will present at the 25 th Annual

Related news

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-03-16 12:13 EST

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

NAMSNewAmsterdam Pharma2026-04-08 12:00 EST

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

LXRXLexicon Pharmaceuticals2026-05-28 12:30 EST

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

LXRXLexicon Pharmaceuticals2026-05-12 12:30 EST

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

RYTMRhythm Pharmaceuticals2026-05-06 12:00 EST

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

VANIVivani Medical2026-05-28 12:30 EST

Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

MNKDMannKind2026-05-27 20:00 EST

MannKind to Present at Jefferies Global Healthcare Conference

MLYSMineralys Therapeutics2026-06-08 20:05 EST

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to sinus rhythm. Atrial Fibrillation...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MISTMilestone Pharmaceuticals Inc.2026-07-03 01:30 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-05-06 12:00 EST

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

Stock data

Close
1.18 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States